ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

ClinicalTrials.gov ID: NCT06765109

Public ClinicalTrials.gov record NCT06765109. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 2:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

Study identification

NCT ID
NCT06765109
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Nuvalent Inc.
Industry
Enrollment
450 participants

Conditions and interventions

Interventions

  • Alectinib Drug
  • Neladalkib (NVL-655) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 16, 2025
Primary completion
Nov 30, 2029
Completion
Nov 30, 2029
Last update posted
May 4, 2026

2025 – 2029

United States locations

U.S. sites
21
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Palo Verde Hematology Oncology Glendale Arizona 85304 Recruiting
Hoag Hospital Newport Beach Newport Beach California 92663 Recruiting
University of California, Irvine Health Orange California 92868 Recruiting
Rocky Mountain Cancer Centers Boulder Colorado 80218 Recruiting
Sylvester Comprehensive Cancer Center Miami Miami Florida 33136 Recruiting
AdventHealth Cancer Institute Orlando Florida 32804 Recruiting
H Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612 Recruiting
Winship Cancer Institute of Emory University Atlanta Georgia 30322 Recruiting
Dana-Farber Cancer Institute Boston Massachusetts 02215 Recruiting
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201 Withdrawn
Washington University Center for Advanced Medicine St Louis Missouri 63110 Recruiting
NYU Langone's Perlmutter Cancer Center New York New York 10016 Recruiting
Memorial Sloan Kettering Cancer Center New York New York 10065 Recruiting
Optum Medical Care, PC Westbury New York 11590 Recruiting
Carolinas Medical Center Charlotte North Carolina 28203 Recruiting
Duke Cancer Center Durham North Carolina 27710 Recruiting
University of Cincinnati Cancer Center Cincinnati Ohio 45267 Recruiting
The Ohio State University Columbus Ohio 43210 Recruiting
SCRI Oncology Partners Nashville Tennessee 37203 Recruiting
Virginia Cancer Specialists Fairfax Virginia 22031 Recruiting
University of Washington - Fred Hutchinson Cancer Center Seattle Washington 98109 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 128 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06765109, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 4, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06765109 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →